Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer) or Lenvima / Kisplyx (Eisai), and Opdivo plus Cabometyx (Exelixis / Ipsen), have revolutionized the first-line treatment of advanced or metastatic disease. The approvals of Keytruda and the HIF-2α inhibitor Welireg (Merck & Co.) for certain subsets of early-stage patients have diversified treatment options. The late-phase pipeline for renal cell carcinoma is largely dominated by immunotherapies and angiogenesis inhibitors, with a continued focus on combinatorial approaches.

Questions answered

• How are immune checkpoint inhibitors shaping drug treatment in the early-stage and advanced or metastatic disease segments?
• What are the opinions of interviewed experts on key current therapies for renal cell carcinoma?
• Which are the most promising emerging regimens in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market over the forecast period?
• Which brands are poised to lead the renal cell carcinoma drug market?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.